An observational study to determine reporting rate of Cases of cerebral vein thrombosis as adverse drug reaction for COVID-19 vaccines authorized in Europe
Latest Information Update: 19 Aug 2021
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 19 Aug 2021 New trial record
- 10 Aug 2021 Results published in the Journal of Thrombosis and Haemostasis